Outcomes

First-in-Human (FIH) Dose Strategy and Protocol Development
We integrate PK/PD, efficacy, and safety data from translational models to inform optimal FIH dose selection. Our data-driven approach provides robust exposure–response insights to support the design of first-in-human clinical protocols.

Biomarker-Driven Clinical Development
Identify and validate decision-enabling biomarkers on patient selection and target modulation to incorporate into clinical trial protocols. Help align discovery, translational, and clinical endpoints for project advancement.

Combination with Standard-of-Care
Evaluate combinations with standard-of-care (SoC) therapies to inform rational clinical development strategies, define optimal dose and scheduling parameters, and elucidate the mechanistic basis of synergistic interactions.